Drug Trial Radar · NCT07553988
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
May 14, 2026
Study completion May 9, 2027
Sponsor
- Lead sponsor
- R-Pharm International, LLCIndustry
- Sponsor type
- Industry
- First posted
- Apr 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of different doses of RS-113 versus abiraterone, as well as to investigate pharmacokinetics profile and to perform a pilot evaluation of pharmacokinetics parameters of RS-113 in patients with metastatic castration-resistant prostate cancer
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
RS-113, 160 mgDrug
Hard gelatin capsules, 80 mg
RS-113, 240 mgDrug
Hard gelatin capsules, 80 mg
RS-113, 320 mgDrug
Hard gelatin capsules, 80 mg
AbirateroneDrug
Tablets, 250 mg
PrednisoloneDrug
Tablets, 5 mg
Androgen deprivation therapy (ADT)Drug
* Goserelin: subcutaneous implant, 3.6 mg or 10.8 mg, or * Leuprorelin: lyophilisate for solution for subcutaneous injection, 7.5 mg or 22.5 mg, or * Triptorelin: lyophilisate for solution for intramuscular injection, 3.75 mg, or * Buserelin: lyophilisate for solution for intramuscular injection, 3.75 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Median Progression-free survival (PFS) at 1 year in RS-113 treatment armsTime frame: Up to day 337 (visit 16)
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
State Budgetary Healthcare Institution of the Arkhangelsk Region "Arkhangelsk Oncology Dispensary"
Arkhangelsk, Russia
Moscow City Clinical Oncology Hospital No. 62 of the Moscow Department of Healthcare
Istra, Russia
Ivanovo Regional Oncology Dispensary
Ivanovo, Russia
Kaluga Regional Clinical Oncology Dispensary
Kaluga, Russia
State Budgetary Healthcare Institution "Leningrad Regional Clinical Hospital"
Kuz'molovskiy, Russia
Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow Healthcare Department
Moscow, Russia
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Moscow, Russia
Federal State Autonomous Institution "National Medical Research Center 'Medical and Rehabilitation Center'" of the Ministry of Health of the Russian Federation
Moscow, Russia
Research Lab LLC
Moscow, Russia
Joint-Stock Company "Medsi Group of Companies"
Moscow, Russia
LLC MSCh "Klinitsist-Klinika Pretor"
Novosibirsk, Russia
Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of Saint-Petersburg"
Saint Petersburg, Russia
City Clinical Oncology Dispensary (Saint Petersburg)
Saint Petersburg, Russia
Siberian State Medical University
Tomsk, Russia
Multidisciplinary Clinical Medical Center "Medical City"
Tyumen, Russia
State Institution of Healthcare of Yaroslavl Region "Regional Oncology Hospital"
Yaroslavl, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.